Q-omics provides the consensus-scored MGAT4B profile across patient tissues and cancer cell-line models. MGAT4B expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MGAT4B is differentially expressed in 15, with the highest sampling consensus in KIRP. Additionally, MGAT4B RNA expression shows 18,766 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, KIRP, and ACC as cancer lineages where MGAT4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MGAT4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MGAT4B survival associations across molecular data types. MGAT4B RNA expression shows survival associations in the most cancer types (28), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MGAT4B RNA expression–survival associations across cancer types. High MGAT4B expression shows unfavorable associations in KICH, LGG, BRCA, CESC and HNSC, but favorable associations in COAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for MGAT4B RNA expression.
This table summarizes MGAT4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MGAT4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MGAT4B shows higher tumor expression in KIRP, BLCA, THCA, KIRC, LIHC and KICH. The KIRP box plot shows higher MGAT4B RNA expression in tumor versus normal tissue (log2 FC = +1.897, t-test p < 0.001).
This table shows molecular features associated with MGAT4B in patient tissues and cancer cell lines. In patient samples, MGAT4B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MGAT4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
